A Single-Center, Investigator-Sponsored Pilot Study to Assess Safety and Biologic Activity of Bromfenac Ophthalmic Solution, 0.09 percent, in Subjects With Diffuse DME [diabetic macular oedema] Refractory to Laser
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bromfenac (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2007 New trial record.